**Study of Guselkumab vs Risankizumab for Crohn's Disease** This study compares two medicines, **guselkumab** and **risankizumab**, to see which works better for people with serious Crohn's Disease. Crohn's Disease is a long-lasting illness that causes painful swelling in the intestines. **Eligibility:** Participants must have had Crohn's Disease for at least 12 weeks. They should have active symptoms, which means they're not feeling well due to the disease. Doctors will check their intestines using a camera (endoscopy) to make sure they're a good fit for the study. People cannot join if they have certain problems like narrow or blocked intestines, need surgery soon, or have had major surgeries recently. Also, if they have cancer now or had it in the last five years, they can't participate. **Key Points:** - **Length of Study:** Participants must follow medication rules and attend check-ups as part of the study. - **Compensation:** Participants may receive compensation for their time and travel. - **Risks:** There may be risks involved, such as side effects from the medication. Before joining, consider if you're comfortable with the study's requirements and potential risks.